Litcius/Paper detail

Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)

Lindsey Sattler, Stephen B. Hanauer, Lisa Malter

2021Current Gastroenterology Reports36 citationsDOI

Topics & Concepts

MedicineAzathioprineInflammatory bowel diseaseTumor necrosis factor alphaCombination therapyInfliximabPharmacologyInternal medicineImmunologyDiseaseInflammatory Bowel DiseaseImmunodeficiency and Autoimmune DisordersSystemic Lupus Erythematosus Research
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate) | Litcius